← Return to PRRT has been approved by the FDA Jan 26, 2018, as expected

Discussion

PRRT has been approved by the FDA Jan 26, 2018, as expected

Neuroendocrine Tumors (NETs) | Last Active: Feb 11, 2023 | Replies (15)
Comment receiving replies
@markmark007

Tom:
My wife is scheduled to begin PRRT on 3/9/2023 @ Fred Hutch - Seattle. The oncologist, after a recent Ga68 C/T scan, recommended this therapy. She has not been evaluated for receptor type 2A presence.
We understand each patient is unique - just want some general guidance.
1. After reading your post, my question is out of ignorance - in any case, should we request that the type 2A amount be checked?
2. What is the minimum threshold?
3. Is Afinitor still used?
Many thanks,
Mark

Jump to this post

Replies to "Tom: My wife is scheduled to begin PRRT on 3/9/2023 @ Fred Hutch - Seattle. The..."
Tom Wilson | @tomewilson | Feb 9, 2023

Hi Mark,

I am not familiar with the term ‘Type 2A’. Please help me. Is this what you mean in the context of staging: Stage IIA describes a tumor larger than 4 cm but 5 cm or less in size that has not spread to the nearby lymph nodes.

Since I’m not sure of the reference to type 2A, I can’t answer the minimum threshold question.

Regarding Afinitor being used to control growth, the answer is yes. In my wife's case she experienced progressive liver disease and so has been on Afinitor for over 4 1/2 years - well past its usual efficacy. Her next treatment may well be PRRT. Sequencing of treatments is very important. You msy have already told me this, but make dure you are seeing a recognized NETs specialist in a high volume NETs center.

Please follow up with any questions.

VIEW AND REPLY